
May 7, 2025
ZENITH ENERGY LTD.
("Zenith" or the "Company")
Admission to trading of Common Shares
Zenith Energy Ltd. ("Zenith" or the "Company") (LSE: ZEN; OSE: ZENA; PINK MARKET: ZENAF), the listed international energy production and development company, confirms that an application has been made for admission to the Transition Category of the FCA Official List and to trading on the Main Market for listed securities of the London Stock Exchange of 58,601,490 common shares of no par value ("Common Shares"). The Common Shares already form part of the Company's outstanding share capital and do not represent a new equity issuance.
Admission for the Common Shares to be admitted to the Transition Category of the FCA Official List and to trading on the Main Market for listed securities of the London Stock Exchange is expected to take place on May 9, 2025 ("Admission").
Following Admission, the number of Common Shares admitted to the Transition Category of the FCA Official List and to trading on the Main Market for listed securities of the London Stock Exchange will be 307,788,707.
Further Information:
Zenith Energy Ltd |
Tel: +1 (587) 315 1279 |
Notes to Editors:
Zenith Energy Ltd. is a revenue generating, independent energy company with energy production, exploration and development assets in North Africa, the US and Europe. The Company is listed on the London Stock Exchange Main Market (LSE: ZEN), the Euronext Growth of the Oslo Stock Exchange (OSE: ZENA) and the Pink Markets of the OTC (OTC PINK: ZENAF).
Zenith's strategic focus is on pursuing development opportunities through the development of proven revenue generating energy production assets, as well as low-risk exploration activities in assets with existing production.
For more information, please visit: www.zenithenergy.ca Twitter: @zenithenergyltd
LinkedIn: https://bit.ly/3A5PRJb
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.